Evidence map›Paper›PMID 41777027›Full record

SynthesisPharmaceutical biology2026

Harnessing nature: a systematic exploration of

Qamar Uddin Ahmed, Nur Adlina Mat Nasir, Taslima Begum, A B M Helal Uddin, Humaira Parveen, Mona O Albalawi, Muhammad Muzaffar Ali Khan Khattak, Syed Najmul Hejaz Azmi, Murni Nazira Sarian, Adelya Desi Kurniawati and 1 more

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Pharmaceutical biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qamar Uddin AhmedDrug Discovery and Synthetic Chemistry Research Group, Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia.
Nur Adlina Mat NasirDrug Discovery and Synthetic Chemistry Research Group, Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia.
Taslima BegumDrug Discovery and Synthetic Chemistry Research Group, Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia.
A B M Helal UddinDrug Discovery and Synthetic Chemistry Research Group, Department of Pharmaceutical Chemistry, Kulliyyah of Pharmacy, International Islamic University Malaysia (IIUM), Kuantan, Pahang, Malaysia.
Humaira ParveenOrganic and Medicinal Chemistry Research Lab., Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Kingdom of Saudi Arabia.
Mona O AlbalawiAnalytical Chemistry Research Laboratory, Department of Chemistry, Faculty of Science, University of Tabuk, Tabuk, Saudi Arabia.
Muhammad Muzaffar Ali Khan KhattakDepartment of Nutrition Sciences, Kulliyyah of Allied Health Sciences, IIUM, Kuantan, Pahang Darul Makmur, Malaysia.
Syed Najmul Hejaz AzmiApplied Sciences Department, College of Applied Sciences and Pharmacy, University of Technology and Applied Sciences-Muscat, Muscat, Sultanate of Oman.
Murni Nazira SarianInstitute of Systems Biology (INBIOSIS), Universiti Kebangsaan Malaysia, Bangi, Selangor, Malaysia.
Adelya Desi KurniawatiDepartment of Nutrition, Faculty of Health Sciences, Universitas Brawijaya, Puncak Dieng Eksklusif, Kunci, Kabupaten Malang, East Jawa, Indonesia.
Zainul Amiruddin ZakariaDepartment of Nutrition, Faculty of Health Sciences, Universitas Brawijaya, Puncak Dieng Eksklusif, Kunci, Kabupaten Malang, East Jawa, Indonesia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

contextCurrent treatments for leishmaniasis and Human African Trypanosomiasis (HAT) are constrained by toxicity, high costs, and the growing threat of parasite resistance. In this context, natural products have emerged as promising alternatives, offering the potential for safer and more cost‑effective therapeutic interventions.

objectiveThis review assesses the antileishmanial and antitrypanosomal activities of medicinal plants, underscoring their significance in addressing parasitic diseases and identifying promising candidates for future drug discovery and development.

methodsFollowing the PRISMA 2020 guidelines, a systematic search was conducted for literature published between 2003 and 2023. Studies were considered eligible if they reported RESULTS AND

conclusionsA total of fifty eligible articles were included. 217 plants demonstrated potent activity (IC₅。 < 10 µg/mL) against

Indexed as

Antiprotozoal AgentsLeishmaniaLeishmaniasisPlant ExtractsPlants, MedicinalTrypanocidal AgentsTrypanosomiasis, AfricanAnimalsHumansTrypanosoma brucei bruceiAntiprotozoal AgentsPlant ExtractsTrypanocidal Agentsantiparasitic compoundsLeishmanicidalmedicinal plantsnatural productstrypanocidal

Identifiers

PMID41777027
PMCPMC12961707

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.